Protein anchoring method, injection medicine and application thereof
Through the bioorthogonal reaction of 1,2,4,5-tetrazine compound and transcyclooctene, the long-acting covalent anchorage of protein drugs in the body is achieved, and the proteomic enrichment of protein drugs in the prior art is solved. The problem of short part half-life improves bioavailability and long-term drug effectiveness.
Patent Information
- Application Number
- CN202411083053.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-22
AI Technical Summary
The existing protein drug anchoring technology is difficult to achieve long-term effect in areas with rich blood flow and vigorous metabolism, and is sensitive to structural changes of enzyme drugs, affecting activity, resulting in short half-life and poor results.
The 1,2,4,5-tetrazine compound is used to react with the transcyclooctene modified exogenous protein to achieve long-term retention of the protein through covalent anchoring, avoiding the glycan components in the tissue site limitations.
Fast covalent anchoring and long-term accumulation of proteins at any site is achieved, bioavailability is improved, the half-life of the drug is extended, and the removal of antibodies is prevented.
Smart Images

Figure CN118987245A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the field of biomedicine, and in particular to a protein anchoring method, an injectable drug and uses thereof. Background Art
[0002] Protein drugs are biologically active protein preparations produced using biotechnology that exert therapeutic effects in the body through specific mechanisms of action.
[0003] Currently, only about 15% of all protein drugs are enzyme drugs approved by the U.S. Food and Drug Administration (FDA). The reason is that although these enzyme drugs are used to treat many diseases such as lysosomal storage diseases, immunodeficiency, leukemia, hemophilia B and thrombosis, and produce certain significant effects. However, there are certain barriers in terms of pharmacokinetics, pharmacodynamics and safety, resulting in many potential enzyme drug candidates still failing in clinical trials due to poor effects. Therefore, the number of enzyme drugs approved by the FDA can be increased by improving enzyme pharmacokinetics, pharmacodynamics and safety by extending the half-life, increasing target accumulation and minimizing immunogenicity.
[0004] Local protein anchoring can help protein drugs maintain a stable conformation and activity in the body through interactions with cell membranes or other cell structures. At the same time, protein drugs are guided to specific cells or tissue sites to achieve precise positioning. This is of great significance for treating specific diseases or targeting specific cell types. In the prior art, sugar-binding proteins (Nature Communications volume 9, Article number: 4943 (2018)) are mainly used to fuse the target protein and G3 (β-galactoside polysaccharide binding protein) for expression. G3 can be tightly bound to a large amount of glycosaminoglycans (CAG) present in the extracellular matrix of the subcutaneous tissue, thereby achieving long-term anchoring of the target protein in the subcutaneous tissue. In addition, one of the domains of placental growth factor-2 (PIGF-2) that can bind to the extracellular matrix (ECM) with high affinity is fused to the growth factor to achieve anchoring of the growth factor at the injection site, promoting osteogenic repair and tissue regeneration (Science 2014, 343, 6173, 885-888).
[0005] In the prior art, the anchoring method of the target protein requires the fusion expression of exogenous sugar-binding protein or extracellular matrix-binding protein on the target protein, and it is usually completely metabolized within a week, especially in parts with rich blood flow and vigorous metabolism (such as muscles, etc.). The strategy of anchoring by sugar-binding protein G3 has a half-life of less than 4 hours, which does not meet the time requirement for long-term effect. Therefore, anchoring cannot achieve long-term effect. In addition, many enzymes are very sensitive to structural changes. Anchoring using the strategy of fusion protein may affect the activity of the enzyme, resulting in greatly reduced drug activity after fusion.
[0006] In summary, at present, there is a lack of a method that can achieve long-term anchoring without being restricted by the glycan composition of the tissue site. Summary of the invention
[0007] In view of this, the purpose of the present disclosure is to solve at least one of the problems existing in the prior art. More specifically, the present disclosure aims to provide a protein anchoring method, comprising the following steps: combining a 1,2,4,5-tetrazine compound, or a salt, solvate or prodrug of the 1,2,4,5-tetrazine compound with a matrix protein;
[0008] A foreign protein modified with trans-cyclooctene is added to cause a bioorthogonal reaction to achieve covalent anchoring of the foreign protein.
[0009] Preferably, the 1,2,4,5-tetrazine compound comprises a monosubstituted 1,2,4,5-tetrazine molecule modified with a cross-linking group, and preferably, the cross-linking group comprises NHS-active ester, acyl chloride or sulfonyl fluoride.
[0010] Preferably, the 1,2,4,5-tetrazine compound includes a compound having a general structural formula as shown in any one of (Formula I) to (Formula VIII):
[0011]
[0012] Wherein, Ra is hydrogen, and Rb, Rc, Rd, Re, and Rf are optional:
[0013] Hydrogen or phenyl,
[0014] Substituted phenyl, containing hydrogen, halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido, alkanoyl or alkynyl,
[0015] Substituted alkanoyl containing halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido or azide,
[0016] unsubstituted alkanoyl or alkynyl, acyl,
[0017] The substituted acyl group contains hydrogen, halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido, alkanoyl or alkynyl.
[0018] Preferably, the method for preparing exogenous protein comprises:
[0019] The plasmid containing the foreign protein gene is transformed into Escherichia coli and cultured;
[0020] Induce the expression of exogenous protein with isopropyl-β-D-thiogalactoside (IPTG) or arabinose, and collect the bacterial precipitate by centrifugation;
[0021] After the bacterial cell precipitation is purified, the exogenous protein is obtained.
[0022] Preferably, the trans-cyclooctene-modified foreign protein is obtained by modifying the foreign protein with trans-cyclooctene-tetraethylene glycol-succinimide active ester.
[0023] Preferably, the bioorthogonal reaction is: a Diels-Alder cycloaddition reaction of a 1,2,4,5-tetrazine compound and trans-cyclooctene; specifically, the dienophilic part of the 1,2,4,5-tetrazine molecule undergoes a Diels-Alder cycloaddition reaction with the double bond of trans-cyclooctene, and the generated dihydropyridazine intermediate is unstable, and further cycloaddition reaction eliminates nitrogen to form a stable final product, and the reaction formula is as follows:
[0024]
[0025] Wherein, R is a para-substituent of Ra in the compounds of (Formula I) to (Formula VIII).
[0026] Preferably, the matrix protein includes matrix protein from subcutaneous, subarticular, and muscle tissues of mammals.
[0027] Preferably, the exogenous protein is selected from α-1 antitrypsin, angiostatin, antihemolytic factor, antibody, apolipoprotein, apoprotein, atrial natriuretic factor, atrial natriuretic polypeptide, atrial peptide, CXC chemokine, T39765, NAP-2, ENA-78, gro-a, gro-b, gro-c, IP-10, GCP-2, NAP-4, SDF-1, PF4, MIG, calcitonin, C-kit ligand, cytokine, CC chemokine, monocyte chemoattractant protein-1, monocyte chemoattractant protein 2, monocyte chemoattractant protein-3, monocyte inflammatory protein-1α, monocyte Nuclear cell inflammatory protein-1β, RANTES, I309, R83915, R91733, HCC1, T58847, D31065, T64262, CD40, CD40 ligand, C-kit ligand, collagen, colony stimulating factor, complement factor 5a, complement inhibitor, complement receptor 1, cytokine, epithelial neutrophil activation peptide-78, MIP-16, MIP-1, epidermal growth factor, epithelial neutrophil activation peptide, erythropoietin, exfoliating toxin, factor IX, factor VII, factor VIII, factor X, fibroblast growth factor , fibrinogen, fibronectin, four-helix bundle protein, G-CSF, glp-1, GM-CSF, glucocerebrosidase, gonadotropin, growth factor, growth factor receptor, hedgehog protein, hemoglobin, hepatocyte growth factor, hirudin, human growth hormone, human serum albumin, ICAM-1, ICAM-1 receptor, LFA-1, LFA-1 receptor, insulin, insulin-like growth factor, IGFI, IGF-II, interferon, IFN-α, IFN-β, IFN-γ, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL- 7. IL-8, IL-9, IL-10, IL-11, IL-12, keratinocyte growth factor, lactoferrin, leukemia inhibitory factor, luciferase, nerve growth factor, neutrophil inhibitory factor, oncostatin M, osteogenic protein, oncogene products, paracitonin, parathyroid hormone, PD-ECSF, PDGF, peptide hormones, pleiotropic growth factor, protein A, protein G, pth, pyrogenic exotoxin A, pyrogenic exotoxin B and pyrogenic exotoxin C, pyy, relaxin, renin, SCF, small biosynthetic protein, soluble complement receptor I, soluble I-CAM1. At least one of soluble interleukin receptor, soluble TNF receptor, somatomedin, somatostatin, growth hormone, streptokinase, superantigen, staphylococcal enterotoxin, SEA, SEB, SECT, SEC2, SEC3, SED, SEE, steroid hormone receptor, superoxide dismutase, toxic shock syndrome toxin, thymosin α1, tissue plasminogen activator, tumor growth factor, tumor necrosis factor, tumor necrosis factor α, tumor necrosis factor β, tumor necrosis factor receptor, VLA-4 protein, VCAM-1 protein, vascular endothelial growth factor, urokinase, mos, ras, raf, met, p53, tat, fos, myc, jun, myb, rel, estrogen receptor, progesterone receptor, testosterone receptor, aldosterone receptor, LDL receptor, and corticosterone.
[0028] In another aspect of the present disclosure, an injectable drug is provided, comprising a monosubstituted 1,2,4,5-tetrazine compound modified with a cross-linking group, preferably, the cross-linking group comprises NHS-active ester, acyl chloride or sulfonyl fluoride; preferably, the injectable drug is used to anchor a protein drug subsequently injected into the same site, wherein, preferably, the protein drug is modified with trans-cyclooctene.
[0029] Preferably, the injectable drug comprises a compound having a general structural formula as shown in any one of (Formula I) to (Formula VIII):
[0030]
[0031] Wherein, Ra is hydrogen, and Rb, Rc, Rd, Re, and Rf are optional:
[0032] Hydrogen or phenyl,
[0033] Substituted phenyl, containing hydrogen, halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido, alkanoyl or alkynyl,
[0034] Substituted alkanoyl containing halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido or azide,
[0035] unsubstituted alkanoyl or alkynyl, acyl,
[0036] Substituted acyl groups contain hydrogen, halogen, alkyl groups having 1 to 7 carbon atoms, substituted alkyl groups having 1 to 7 carbon atoms, alkoxy groups having 1 to 7 carbon atoms, azido groups, alkanoyl groups or alkynyl groups;
[0037] Or a salt, solvate or prodrug of a compound represented by any one of (Formula I) to (Formula VIII).
[0038] The present disclosure further provides a protein anchoring method for in situ cross-linking, bioorthogonal reaction, biomolecule labeling, drug delivery, and protein function regulation.
[0039] The present disclosure further provides a 1,2,4,5-tetrazine compound for use in in situ crosslinking, bioorthogonal reaction, biomolecule labeling, drug delivery, and protein function regulation.
[0040] The present disclosure further provides a use of a 1,2,4,5-tetrazine compound for anchoring a protein. Preferably, the protein is a protein modified by trans-cyclooctene.
[0041] The present disclosure further provides an injectable drug for use in in situ cross-linking, bioorthogonal reaction, biomolecule labeling, drug delivery, and protein function regulation.
[0042] The technical solution disclosed in this disclosure can produce the following beneficial effects:
[0043] 1. The 1,2,4,5-tetrazine compounds provided in the present disclosure can be used for in situ cross-linking and are molecules that are very suitable for in vivo bioorthogonal reactions. The use of in vivo bioorthogonal reactions can shorten the reaction time, increase the long-term effectiveness of the cross-linked products, and improve the bioavailability.
[0044] 2. The protein anchoring method provided in the present disclosure can anchor any protein at any site through a two-step method, further broadening the application scope of proteins in the biomedical field, and also realizing rapid covalent anchoring of proteins, long-term accumulation at the site and long-term residence, and can prevent antibody clearance.
[0045] 3. Compared with non-covalent anchoring methods, the protein anchoring method provided by the present invention is superior to the existing technology in terms of anchoring time and universality, and does not require the fusion of other exogenous proteins, is not limited by the glycan components of tissue sites, and can be modified with trans-cyclooctene (TCO) on all wild-type proteins through a simple one-step trans-cyclooctene-tetraethylene glycol-succinimide active ester (TCO-PEG4-NHS ester) modification, thereby anchoring proteins at any injection site. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] The above and other features, advantages and aspects of the embodiments of the present disclosure will become more apparent with reference to the following detailed description in conjunction with the accompanying drawings. In the accompanying drawings, the same or similar reference numerals represent the same or similar elements, wherein:
[0047] Figure 1 This is a schematic diagram of the process of exogenous protein anchoring based on bioorthogonal reaction in the embodiment of the present disclosure;
[0048] Figure 2This is a diagram showing the anchoring of sfGFP in the subcutaneous tissue of balb / c nude mice for 7 days in Example 2 of the present disclosure;
[0049] The left picture shows the comparison of the fluorescence intensity changes at the injection site for 1 hour between mice not injected with compound 1 and mice injected with compound 1;
[0050] The middle figure is a comparison of the fluorescence intensity changes at the injection site on day 7 between mice not injected with compound 1 and mice injected with compound 1;
[0051] The right figure is a curve chart showing the change in the relative average radiation efficiency ratio of the injection site over time from day 0 to day 7 for mice not injected with compound 1 and mice injected with compound 1.
[0052] Figure 3 This is a diagram showing the anchoring of mCherry in the subcutaneous tissue of balb / c nude mice for 7 days in Example 3 of the present disclosure;
[0053] The left picture shows the comparison of the fluorescence intensity changes at the injection site for 1 hour between mice not injected with compound 1 and mice injected with compound 1;
[0054] The middle figure is a comparison of the fluorescence intensity changes at the injection site on day 7 between mice not injected with compound 1 and mice injected with compound 1;
[0055] The right figure is a curve chart showing the change in the relative average radiation efficiency ratio of the injection site over time from day 0 to day 7 for mice not injected with compound 1 and mice injected with compound 1.
[0056] Figure 4 This is a diagram showing the anchoring of sfGFP in the subcutaneous tissue of the knee of balb / c mice for 73 days in Example 4 of the present disclosure:
[0057] The left and middle images are comparisons of the changes in fluorescence intensity at the injection site at different times for mice that were not injected with compound 1 and mice that were injected with compound 1;
[0058] The right figure is a bar graph showing the change in the relative average radiation efficiency ratio over time for mice not injected with compound 1 and mice injected with compound 1. DETAILED DESCRIPTION
[0059] In order to make the objectives, technical solutions and advantages of the present disclosure more clearly understood, the present disclosure is further described in detail below in conjunction with the accompanying drawings and examples. The embodiments of the present invention and their descriptions are only used to explain the present invention, but these examples and descriptions do not limit the scope of the present invention.
[0060] It should be understood that the order of steps or the order in which certain actions are performed is not important as long as the present disclosure is still operable. In addition, two or more steps or actions can be performed simultaneously.
[0061] The use of any and all examples or exemplary language, such as "for example" or "including", herein is intended only to better illustrate the present disclosure and does not limit the scope of the present disclosure unless the claims are set forth. No language in this specification should be construed as indicating any non-claimed element is essential to the practice of the present disclosure.
[0062] Unless otherwise specified, all terms used herein, including technical terms and scientific terms, have the same meaning as those commonly understood by those skilled in the art. Terms defined in commonly used dictionaries should be interpreted as having the same meaning as in the relevant technical context, and unless clearly defined in the specification, these terms are not interpreted as having formal meanings in an idealized or overly formal sense. It should be understood that exogenous proteins, target proteins, wild-type proteins, etc. herein are all the same references, and those skilled in the art can understand that no ambiguity should be generated and should not affect the scope of protection of this application.
[0063] In addition, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values in the specific embodiments have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual test methods. Therefore, unless otherwise expressly stated, it should be understood that all ranges, quantities, values and percentages used in this disclosure are modified by "about". Here, "about" generally means that the actual value is within plus or minus 10%, 5%, 1% or 0.5% of a specific value or range.
[0064] The various reagents, raw materials, instruments or equipment involved below can be purchased and obtained from the market.
[0065] In one embodiment, if Figure 1 As shown, a 1,2,4,5-tetrazine compound, or a salt, solvate or prodrug of a 1,2,4,5-tetrazine compound is injected into the subcutaneous / muscle tissue of a mouse. After the injection, the mouse waits for 20-30 minutes to allow the unreacted compound to be cleared through the blood circulation in the body. Then, a trans-cyclooctene-modified target protein is injected into the same position. The trans-cyclooctene and the tetrazine molecules on the compound undergo a bioorthogonal reaction and couple at the injection site, thereby achieving in vivo anchoring of the exogenous protein.
[0066] In a preferred embodiment, the 1,2,4,5-tetrazine compound comprises a monosubstituted 1,2,4,5-tetrazine molecule modified with a cross-linking group, wherein the cross-linking group comprises NHS-active ester, acyl chloride or sulfonyl fluoride.
[0067] In a preferred embodiment, the 1,2,4,5-tetrazine compound includes a compound having a general structural formula as shown in any one of (Formula I) to (Formula VIII):
[0068]
[0069] Wherein, Ra is hydrogen, and Rb, Rc, Rd, Re, and Rf are optional:
[0070] Hydrogen or phenyl,
[0071] Substituted phenyl, containing hydrogen, halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido, alkanoyl or alkynyl,
[0072] Substituted alkanoyl containing halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido or azide,
[0073] unsubstituted alkanoyl or alkynyl, acyl,
[0074] The substituted acyl group contains hydrogen, halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido, alkanoyl or alkynyl.
[0075] In one embodiment, the 1,2,4,5-tetrazine compound is used for anchoring a protein; in a preferred embodiment, the anchored protein is a protein modified with trans-cyclooctene.
[0076] In one embodiment, a 1,2,4,5-tetrazine compound is used to prepare a protein-anchored drug; in a preferred embodiment, the protein-anchored drug is used to anchor a protein modified by trans-cyclooctene.
[0077] In one embodiment of the present disclosure, the 1,2,4,5-tetrazine compound is used for in situ cross-linking, bioorthogonal reaction, biomolecule labeling, drug delivery, and protein function regulation.
[0078] In one embodiment, a 1,2,4,5-tetrazine compound, or a salt, solvate or prodrug of a 1,2,4,5-tetrazine compound is used to bind to a matrix protein, and a trans-cyclooctene-modified exogenous protein is added to cause a covalent addition bioorthogonal reaction to achieve covalent anchoring of the exogenous protein.
[0079] It should be understood that bioorthogonal reactions are a type of chemical reactions that are high-yield, highly selective, and can be performed in biological systems (aqueous solutions, room temperature), and that the molecules that undergo bioorthogonal reactions should not or substantially not react with existing substances in the body. In addition to this embodiment, bioorthogonal reactions can also be used for coupling modification of proteins with small molecules (or macromolecules), labeling of intracellular proteins, tumor pre-targeting imaging, cell surface super-resolution imaging, and the like.
[0080] In a preferred embodiment, the method for preparing exogenous protein comprises:
[0081] The plasmid containing the foreign protein gene is transformed into Escherichia coli and cultured;
[0082] Induce the expression of exogenous protein with isopropyl-β-D-thiogalactoside (IPTG) or arabinose, and collect the bacterial precipitate by centrifugation;
[0083] After the bacterial cell precipitation is purified, the exogenous protein is obtained.
[0084] In a preferred embodiment, the trans-cyclooctene-modified exogenous protein is obtained by modifying the exogenous protein with trans-cyclooctene-tetraethylene glycol-succinimide active ester, wherein the bioorthogonal reaction is:
[0085] The dienophilic part of the 1,2,4,5-tetrazine molecule undergoes a Diels-Alder cycloaddition reaction with the double bond of trans-cyclooctene. The generated dihydropyridazine intermediate is unstable. Further cycloaddition reaction eliminates nitrogen to form a stable final product, that is, the 1,2,4,5-tetrazine compound undergoes a Diels-Alder cycloaddition reaction with trans-cyclooctene; the reaction formula is as follows:
[0086]
[0087] Wherein, R is the para-substituent of Ra in the compounds of (Formula I) to (Formula VIII), and the 1,2,4,5-tetrazine molecule (Tz) and trans-cyclooctene (TCO) undergo a Diels-alder cycloaddition reaction (IEDDA).
[0088] It should be understood that the inverse electron demand Diels-alder cycloaddition reaction (IEDDA) has a fast reaction rate, few by-products, can modify proteins at low concentrations, and has good biocompatibility, and can achieve ultrafast reactions in living bodies without causing serious toxicity.
[0089] The extremely fast bioorthogonal reaction of tetrazine-trans-cyclooctene is not limited by the glycan composition of the tissue site, and can achieve long-term anchoring in the muscle site. This embodiment uses a two-step method to first inject a monosubstituted 1,2,4,5-tetrazine molecule modified with a cross-linking group (NHS-active ester, acyl chloride, sulfonyl fluoride, etc.) into the target site, cross-link with the matrix protein present at the injection site, and covalently anchor the tetrazine molecule at the injection site. Then inject the protein modified with trans-cyclooctene, so as to achieve long-term accumulation of the target protein at the injection site, and play a long-term role; achieve the long-term effect of protein drugs and accumulation at the injection site, and prevent the clearance of antibodies.
[0090] In a preferred embodiment, the matrix protein comprises matrix protein from subcutaneous, subarticular, and muscle tissues of mammals.
[0091] In a preferred embodiment, the exogenous protein is selected from alpha-1 antitrypsin, angiostatin, antihemolytic factor, antibody, apolipoprotein, apoprotein, atrial natriuretic factor, atrial natriuretic polypeptide, atrial peptide, CXC chemokine, T39765, NAP-2, ENA-78, gro-a, gro-b, gro-c, IP-10, GCP-2, NAP-4, SDF-1, PF4, MIG, calcitonin, C-kit ligand, cytokine, CC chemokine, monocyte chemoattractant protein-1, monocyte chemoattractant protein 2, monocyte chemoattractant protein-3, monocyte inflammatory protein -1α, monocyte inflammatory protein-1β, RANTES, I309, R83915, R91733, HCC1, T58847, D31065, T64262, CD40, CD40 ligand, C-kit ligand, collagen, colony stimulating factor, complement factor 5a, complement inhibitor, complement receptor 1, cytokine, epithelial neutrophil activation peptide-78, MIP-16, MIP-1, epidermal growth factor, epithelial neutrophil activation peptide, erythropoietin, exfoliating toxin, factor IX, factor VII, factor VIII, factor X, fibroblast growth factor, Growth factor, fibrinogen, fibronectin, four-helix bundle protein, G-CSF, glp-1, GM-CSF, glucocerebrosidase, gonadotropin, growth factor, growth factor receptor, hedgehog protein, hemoglobin, hepatocyte growth factor, hirudin, human growth hormone, human serum albumin, ICAM-1, ICAM-1 receptor, LFA-1, LFA-1 receptor, insulin, insulin-like growth factor, IGFI, IGF-II, interferon, IFN-α, IFN-β, IFN-γ, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, I L-7, IL-8, IL-9, IL-10, IL-11, IL-12, keratinocyte growth factor, lactoferrin, leukemia inhibitory factor, luciferase, nerve growth factor, neutrophil inhibitory factor, oncostatin M, osteogenic protein, oncogene products, paracitonin, parathyroid hormone, PD-ECSF, PDGF, peptide hormones, pleiotropic growth factor, protein A, protein G, pth, pyrogenic exotoxin A, pyrogenic exotoxin B and pyrogenic exotoxin C, pyy, relaxin, renin, SCF, small biosynthetic protein, soluble complement receptor I, soluble I-CAM1. At least one of soluble interleukin receptor, soluble TNF receptor, somatomedin, somatostatin, growth hormone, streptokinase, superantigen, staphylococcal enterotoxin, SEA, SEB, SECT, SEC2, SEC3, SED, SEE, steroid hormone receptor, superoxide dismutase, toxic shock syndrome toxin, thymosin α1, tissue plasminogen activator, tumor growth factor, tumor necrosis factor, tumor necrosis factor α, tumor necrosis factor β, tumor necrosis factor receptor, VLA-4 protein, VCAM-1 protein, vascular endothelial growth factor, urokinase, mos, ras, raf, met, p53, tat, fos, myc, jun, myb, rel, estrogen receptor, progesterone receptor, testosterone receptor, aldosterone receptor, LDL receptor, and corticosterone.
[0092] In one embodiment of the present disclosure, the protein anchoring method is used for in situ cross-linking, bioorthogonal reaction, biomolecule labeling, drug delivery, and protein function regulation.
[0093] In one embodiment of the present disclosure, an injectable drug is provided, which includes a monosubstituted 1,2,4,5-tetrazine molecule modified with a cross-linking group; in a preferred embodiment, the cross-linking group includes NHS-active ester, acyl chloride or sulfonyl fluoride; in a preferred embodiment, the injectable drug is used to anchor a protein drug subsequently injected into the same site; in a preferred embodiment, the protein drug is modified with trans-cyclooctene; in a preferred embodiment, the injectable drug includes compounds of (Formula I) to (Formula VIII):
[0094]
[0095] Wherein, Ra is hydrogen, and Rb, Rc, Rd, Re, and Rf are optional:
[0096] Hydrogen or phenyl,
[0097] Substituted phenyl, containing hydrogen, halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido, alkanoyl or alkynyl,
[0098] Substituted alkanoyl containing halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido or azide,
[0099] unsubstituted alkanoyl or alkynyl, acyl,
[0100] Substituted acyl groups contain hydrogen, halogen, alkyl groups having 1 to 7 carbon atoms, substituted alkyl groups having 1 to 7 carbon atoms, alkoxy groups having 1 to 7 carbon atoms, azido groups, alkanoyl groups or alkynyl groups;
[0101] Or a salt, solvate or prodrug of a compound of (Formula I) to (Formula VIII).
[0102] In one embodiment, the injected drug is used for in situ cross-linking, bioorthogonal reaction, biomolecule labeling, drug delivery, and protein function regulation.
[0103] In the disclosed embodiment, the specific implementation methods of fluorescent protein small animal in vivo imaging verification of protein anchoring are as follows, and the relevant specific implementation methods will not be repeated in the following text:
[0104] Preparation of target protein
[0105] Expression of the target protein in E. coli BL21 (DE3) strain: The plasmid with the target protein open reading frame fused with the purification tag 6*His was transformed into the BL21 (DE3) competent strain by chemical transformation, spread on the antibiotic plate containing the corresponding resistance, and inverted cultured at 37 degrees overnight. After overnight culture, pick a single colony to 2ml 2*YT medium, culture at 37 degrees for 10 hours, expand the culture to 100ml medium at a volume ratio of 1:50, culture at 37 degrees for 1.5-2h until OD600nm = 0.6, add 0.4mM isopropyl-β-D-thiogalactoside (IPTG) or arabinose as an inducer for protein expression, and use a desktop centrifuge at 5000rpm for 15 minutes to collect the bacterial precipitate, and after ultrasonic disruption, follow Ni 2+ The general steps of metal ion affinity chromatography are to purify the target protein containing 6*His histidine tag, and freeze it in a -80 degree refrigerator for future use.
[0106] Trans-cyclooctene modified target protein
[0107] The target protein to be modified was diluted to 20uM with phosphate buffer solution (PBS, pH = 7.4), and 200uM trans-cyclooctene-tetraethylene glycol-succinimide active ester (TCO-PEG4-NHS ester) was added. The reaction was carried out at 25 degrees for 5 hours, and the liquid was changed three times with a 10KDa ultrafiltration tube (Millpore) to completely remove the unreacted TCO-PEG4-NHS ester. The protein modified with trans-cyclooctene was frozen in a -80 degree refrigerator for later use.
[0108] Eight-week-old balb / c nude mice (n=3) were selected as the experimental group and the control group respectively:
[0109] The experimental group was injected with 10 nmol of compound 1 subcutaneously in the right buttocks, and then injected with TCO-modified green fluorescent protein (sfGFP) or red fluorescent protein (mCherry) after waiting for 30 minutes.
[0110] The control group was injected with PBS of the same volume as compound 1 injected in the experimental group at the same time point, and the subsequent operations were the same as those of the experimental group.
[0111] Using the fluorescence channel of a small animal imaging system (such as IVIS Lumina 2), image the mice at 1 hour, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, and 7 days after injection, and record the changes in fluorescence intensity at the injection site.
[0112] The images were processed using living image 4.3.1 software, and data analysis and curve fitting were performed using GraphPad prism 8. Finally, the curves of the change of fluorescence intensity at the injection site over time in the control group and the experimental group were obtained.
[0113] Example 1: Preparation of Compound 1 for in situ cross-linking
[0114] Preliminary reaction and oxidation: 1 g (5.6 mmol) of 4-(4-cyano-1h-imidazole-1-yl)butyric acid, 2.3 g (22.4 mmol) of formamidine acetate, 4.3 ml (89.6 mmol) of hydrazine hydrate, and 0.145 ml (1.68 mmol) of 3-mercaptopropionic acid (1.68 mmol) were mixed and reacted at 45 ° C for 2 hours. After the reaction was completed, 7 g of sodium nitrite (NaNO2) was added to the reaction solution for oxidation treatment, and the pH value of the reaction system was adjusted to between 2 and 3 to ensure the subsequent extraction efficiency.
[0115] Extraction and purification: The reaction solution after the above oxidation was extracted with ethyl acetate (EtOAc), 200 ml each time, for a total of 4 extractions. After the extracts were combined, they were concentrated to a residual volume of about 20-30 ml, and then purified by silica gel column chromatography. The eluent ratio was ethyl acetate: methanol: acetic acid = 100: 3: 0.1 (EtOAc: MeOH: HOAc = 100: 3: 0.1). After purification, the crude product was a red oily crude product, and no further purification was required. The yield was 0.17 g.
[0116]
[0117] Compound synthesis: The crude product obtained in the previous step was directly used to synthesize compound 1.
[0118] 0.17 g of the crude product from the previous step was dissolved in 20 ml of dichloromethane (DCM), 0.12 g of 1-hydroxypyridine-2,5-dione was added, and then 0.22 g of dicyclohexylcarbazine (DCC) was added. The resulting solution was stirred at room temperature for 15 hours to complete the reaction. After the reaction was completed, the mixture was directly purified by silica gel column chromatography (eluent: ethyl acetate, EA) to obtain the desired red solid, i.e., compound 1, with a yield of 110 mg and a total yield of 6%.
[0119]
[0120] Product characterization: The compound was structurally confirmed by hydrogen nuclear magnetic resonance (1H NMR, 400MHz, Chloroform-d) and carbon nuclear magnetic resonance (13C NMR, 101MHz, CDCl3), and its molecular weight was verified by high-resolution mass spectrometry (HRMS). The specific data are as follows:
[0121] 1H NMR (400MHz, Chloroform-d) δ10.10(s,1H),8.38(s,1H),8.08(s,1H),4.72(t,J=6.9Hz,2H),2.86(s,4H),2.69(t,J=6.9Hz,2H),2.32(p,J=6.9Hz,2H).
[0122] 13C NMR (101MHz, CDCl3) δ169.12,167.81,162.21,156.81,144.34,129.51,124.77,46.72,27.82,26.19,25.74.
[0123] HRMS[M+H]+m / z calcd.for[C13H14N7O4]+332.1107,found332.1104.
[0124] The general structural principles of the compounds of Formula I to Formula VIII disclosed in the present invention are similar, and their preparation methods can all be prepared by the preparation scheme of Compound 1 in the embodiment, therefore, the preparation of the compounds is not described in detail in the present invention. Not limited to the preparation methods in the embodiments, those skilled in the art can also obtain the compounds of Formula I to Formula VIII by other preparation methods.
[0125] Compound II:
[0126]
[0127] The crude product obtained in the previous step was directly used to synthesize compound 2. 0.17 g of the crude product in the previous step was dissolved in 20 ml of dichloromethane (DCM), 115 ul of triethylamine was added, the temperature was lowered to -40 degrees Celsius, 122 ul of cyanuric fluoride was added dropwise, and after the addition was completed, the temperature was raised to -10 degrees Celsius to react for 1 hour. After the reaction was completed, the reaction solution was washed three times with ice water (20 mL×3), the organic phase was dried with anhydrous sodium sulfate, and after drying, column chromatography was used to separate 0.15 g of compound 2.
[0128] Compound III:
[0129]
[0130] The crude product obtained in the previous step was directly used to synthesize compound 3. 0.17 g of the crude product in the previous step was dissolved in 20 ml of dichloromethane (DCM), cooled to 0 degrees Celsius, and 110 ul of dichlorothionyl was added dropwise. After the addition was completed, the reaction was carried out at 0 degrees Celsius for 1 hour. After the reaction was completed, the reaction solution was subjected to rotary evaporation to remove the solvent, and the organic phase was dried over anhydrous sodium sulfate. After drying, 0.13 g of compound 3 was obtained by column chromatography.
[0131] Compound IV:
[0132]
[0133] The crude product obtained in the previous step was directly used to synthesize compound 4. 0.17g of the crude product in the previous step was dissolved in 20ml of ultra-dry dichloromethane (DCM), cooled to 0 degrees Celsius, and 293ul of ultra-dry pyridine and 339ul of phosphorus oxychloride were added dropwise, and finally 0.38g of p-aminobenzenesulfonyl fluoride was added. The mixture was returned to room temperature and reacted for 5h. After the reaction was completed, the reaction solution was washed three times with ice water (20mL×3), and the organic phase was dried with anhydrous sodium sulfate. After drying, 0.1g of compound 4 was obtained by column chromatography.
[0134] For the preparation of compounds V to VIII, it is only necessary to replace the "crude product obtained in the previous step" in the preparation method of compounds I to IV with:
[0135]
[0136] The other raw materials and feed ratios in the subsequent preparation process and the reaction conditions remain unchanged (V corresponds to I, VI corresponds to II, VII corresponds to III, and VIII corresponds to IV), and compounds V to VIII can be obtained through a one-step reaction.
[0137] Example 2 Long-term subcutaneous anchoring of green fluorescent protein in balb / c nude mice
[0138] Modification of green fluorescent protein: Ni 2+The green fluorescent protein purified by metal ion affinity chromatography was diluted to 20uM with phosphate buffer solution (PBS, pH=7.4), and 200uM TCO-PEG4-NHS ester was added. The reaction was carried out at 25 degrees for 5 hours, and the solution was changed three times with an ultrafiltration tube (Millpore) with a molecular weight cutoff of 10KDa to completely remove the unreacted TCO-PEG4-NHS ester to obtain the sfGFP protein modified with TCO, hereinafter referred to as sfGFP-TCO.
[0139] Verification of the long-term anchoring effect in vivo: 8-week-old balb / c nude mice (n=3) were selected as the experimental group and the control group respectively:
[0140] The experimental group was injected subcutaneously with 10 nmol of compound 1 in the right buttocks, and then injected with 0.25 nmol of sfGFP-TCO after waiting for 30 minutes.
[0141] The control group was injected with PBS of the same volume as compound 1 injected in the experimental group at the corresponding time points, and the subsequent operations were the same as those of the experimental group.
[0142] Using the fluorescence channel of a small animal imaging system (such as IVIS Lumina 2), image the mice at 1 hour, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, and 7 days after injection, and record the changes in fluorescence intensity at the injection site.
[0143] Living Image 4.3.1 software was used to process the obtained images, and GraphPad Prism 8 was used for data analysis and curve fitting. The horizontal axis was the residence time (days) after protein injection, and the vertical axis was the ratio of the fluorescence intensity at the injection site to the fluorescence intensity at the non-injection site (i.e., the relative average radiation efficiency ratio). Finally, the curves of the change of fluorescence intensity at the injection site over time were obtained for the control group and the experimental group, respectively.
[0144] Results and analysis: From Figure 2 It can be seen that in mice not injected with compound 1, the fluorescence intensity of sfGFP was greatly reduced 1 hour after injection, while in mice injected with compound 1, no obvious decrease in the fluorescence intensity of sfGFP was observed from 1 day to 7 days after injection, which proves the long-term and durable effect of the present invention on the anchoring of exogenous proteins.
[0145] Example 3 Long-term subcutaneous anchoring of red fluorescent protein in balb / c nude mice
[0146] Modification of red fluorescent protein: using Ni 2+The red fluorescent protein (mCherry) purified by metal ion affinity chromatography was diluted to 20uM with phosphate buffer solution (PBS, pH=7.4), and 200uM TCO-PEG4-NHSester was added. The reaction was carried out at 25 degrees for 5 hours, and the solution was changed three times with a 10KDa ultrafiltration tube (Millpore) to completely remove the unreacted TCO-PEG4-NHS ester to obtain the mCherry protein modified with TCO, hereinafter referred to as mCherry-TCO.
[0147] Verification of the long-term anchoring effect in vivo: 8-week-old balb / c nude mice (n=3) were selected as the experimental group and the control group respectively:
[0148] The experimental group was injected subcutaneously with 10 nmol of compound 1 in the right buttocks, and then injected with 0.25 nmol of mCherry-TCO after waiting for 30 minutes.
[0149] The control group was injected with PBS of the same volume as compound 1 injected in the experimental group at the corresponding time points, and the subsequent operations were the same as those of the experimental group.
[0150] Using the fluorescence channel of a small animal imaging system (such as IVIS Lumina 2), image the mice at 1 hour, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, and 7 days after injection, and record the changes in fluorescence intensity at the injection site.
[0151] Living Image 4.3.1 software was used to process the obtained images, and GraphPad Prism 8 was used for data analysis and curve fitting. The horizontal axis was the residence time (days) after protein injection, and the vertical axis was the ratio of the fluorescence intensity at the injection site to the fluorescence intensity at the non-injection site. Finally, the curves of the change of fluorescence intensity at the injection site with time were obtained for the control group and the experimental group respectively.
[0152] Results and analysis: From Figure 3 It can be seen that in mice not injected with compound 1, the fluorescence intensity of mCherry basically disappeared 2 days after injection, while in mice injected with compound 1, the fluorescence intensity of mCherry slowly decayed from 1 day to 7 days after injection, which may be related to the stability of the mCherry protein itself, proving the long-term and durable effect of the present invention on the anchoring of exogenous proteins.
[0153] Example 4 Long-term anchoring of green fluorescent protein in the subcutaneous tissue of the knee of immune-normal balb / c mice
[0154] 8-week-old balb / c mice (n=3) were selected as the experimental group and the control group respectively:
[0155] The experimental group was injected subcutaneously with 10 nmol of compound 1 in the right knee, and then injected with 0.25 nmol of sfGFP-TCO after waiting for 30 minutes.
[0156] The control group was injected with PBS of the same volume as compound 1 injected in the experimental group at the same time point, and the subsequent operations were the same as those of the experimental group.
[0157] Using the fluorescence channel of a small animal imaging system (such as IVIS Lumina 2), the mice were imaged at 1 hour, 2 days, 10 days, 25 days, 32 days, 47 days, 60 days, and 73 days after injection, and the changes in fluorescence intensity at the injection site were recorded.
[0158] The images were processed using living image 4.3.1 software, and GraphPad prism 8 was used for data analysis and curve fitting. The horizontal axis was the residence time (days) after protein injection, and the vertical axis was the fluorescence intensity at the injection site. Finally, bar graphs of the changes in fluorescence intensity at the injection site over time were obtained for the control group and the experimental group, respectively.
[0159] from Figure 4 It can be seen that in mice not injected with compound 1, the fluorescence intensity of sfGFP was greatly reduced 1 hour after injection, while in mice injected with compound 1, no obvious decrease in the fluorescence intensity of sfGFP was observed from 2 days to 73 days after injection, which proves the long-term and durable anchoring of exogenous proteins by the present invention and can prevent the anchored exogenous proteins from being cleared by antibodies during long-term residence.
[0160] In addition to the compound 1 verified in the aforementioned Examples 1 to 4, it has been experimentally verified that the compounds represented by Formula II to Formula VIII can obtain similar effects in the same experiment.
[0161] In summary, the present invention has created a simple, efficient and universal new method for protein anchoring, which comprehensively improves the application efficiency of proteins in organisms and opens up new avenues for research and treatment in the biomedical field.
[0162] Based on the above, those skilled in the art will understand that the technical solutions claimed in the present disclosure and their equivalent technical solutions will be obvious. In addition, those skilled in the art can also make appropriate modifications and changes to the disclosed technical solutions as needed, and these modified and improved technical solutions are also within the scope of protection of the claims of the present disclosure.
Claims
1. A method for protein anchoring, It is characterized in that The following steps are involved: conjugating a 1,2,4,5-tetrazine compound, or a salt, solvate, or prodrug of the 1,2,4,5-tetrazine compound to a substrate protein; A foreign protein modified with trans-cyclooctene is added to cause a bioorthogonal reaction to achieve covalent anchoring of the foreign protein.
2. The method according to claim 1, It is characterized in that The 1,2,4,5-tetrazine compound includes a monosubstituted 1,2,4,5-tetrazine molecule modified with a cross-linking group, wherein the cross-linking group includes NHS-active ester, acyl chloride or sulfonyl fluoride.
3. The method according to claim 1, It is characterized in that The 1,2,4,5-tetrazine compound includes a compound having a general structural formula as shown in any one of (Formula I) to (Formula VIII): Wherein, Ra is hydrogen, and Rb, Rc, Rd, Re, and Rf are optional: Hydrogen or phenyl, Substituted phenyl, containing hydrogen, halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido, alkanoyl or alkynyl, Substituted alkanoyl containing halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido or azide, unsubstituted alkanoyl or alkynyl, acyl, The substituted acyl group contains hydrogen, halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido, alkanoyl or alkynyl.
4. The method according to claim 1, It is characterized in that The method for preparing the exogenous protein comprises: The plasmid containing the foreign protein gene is transformed into Escherichia coli and cultured; Induce the expression of exogenous proteins with isopropyl-β-D-thiogalactoside or arabinose, and collect the bacterial precipitate by centrifugation; After the bacterial cell precipitation is purified, the exogenous protein is obtained.
5. The method according to claim 1, It is characterized in that The trans-cyclooctene-modified exogenous protein is obtained by modifying the exogenous protein with trans-cyclooctene-tetraethylene glycol-succinimide active ester.
6. The method according to claim 1, It is characterized in that The bioorthogonal reaction is a Diels-Alder cycloaddition reaction between the 1,2,4,5-tetrazine compound and trans-cyclooctene.
7. The method according to claim 1, It is characterized in that The matrix proteins include proteins from subcutaneous, subarticular and muscle tissues of mammals.
8. The method according to claim 1, It is characterized in that The exogenous protein is selected from α-1 antitrypsin, angiostatin, antihemolytic factor, antibody, apolipoprotein, apoprotein, atrial natriuretic factor, atrial natriuretic polypeptide, atrial peptide, CXC chemokine, T39765, NAP-2, ENA-78, gro-a, gro-b, gro-c, IP-10, GCP-2, NAP-4, SDF-1, PF4, MIG, calcitonin, C-kit ligand, cytokine, CC chemokine, monocyte chemoattractant protein-1, monocyte chemoattractant protein 2, monocyte chemoattractant protein-3, monocyte inflammatory protein-1α, mono Nuclear cell inflammatory protein-1β, RANTES, I309, R83915, R91733, HCC1, T58847, D31065, T64262, CD40, CD40 ligand, C-kit ligand, collagen, colony stimulating factor, complement factor 5a, complement inhibitor, complement receptor 1, cytokine, epithelial neutrophil activation peptide-78, MIP-16, MIP-1, epidermal growth factor, epithelial neutrophil activation peptide, erythropoietin, exfoliating toxin, factor IX, factor VII, factor VIII, factor X, fibroblast growth factor , fibrinogen, fibronectin, four-helix bundle protein, G-CSF, glp-1, GM-CSF, glucocerebrosidase, gonadotropin, growth factor, growth factor receptor, hedgehog protein, hemoglobin, hepatocyte growth factor, hirudin, human growth hormone, human serum albumin, ICAM-1, ICAM-1 receptor, LFA-1, LFA-1 receptor, insulin, insulin-like growth factor, IGFI, IGF-II, interferon, IFN-α, IFN-β, IFN-γ, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL- 7. IL-8, IL-9, IL-10, IL-11, IL-12, keratinocyte growth factor, lactoferrin, leukemia inhibitory factor, luciferase, nerve growth factor, neutrophil inhibitory factor, oncostatin M, osteogenic protein, oncogene products, paracitonin, parathyroid hormone, PD-ECSF, PDGF, peptide hormones, pleiotropic growth factor, protein A, protein G, pth, pyrogenic exotoxin A, pyrogenic exotoxin B and pyrogenic exotoxin C, pyy, relaxin, renin, SCF, small biosynthetic protein, soluble complement receptor I, soluble I-CAM1. At least one of soluble interleukin receptor, soluble TNF receptor, somatomedin, somatostatin, growth hormone, streptokinase, superantigen, staphylococcal enterotoxin, SEA, SEB, SECT, SEC2, SEC3, SED, SEE, steroid hormone receptor, superoxide dismutase, toxic shock syndrome toxin, thymosin α1, tissue plasminogen activator, tumor growth factor, tumor necrosis factor, tumor necrosis factor α, tumor necrosis factor β, tumor necrosis factor receptor, VLA-4 protein, VCAM-1 protein, vascular endothelial growth factor, urokinase, mos, ras, raf, met, p53, tat, fos, myc, jun, myb, rel, estrogen receptor, progesterone receptor, testosterone receptor, aldosterone receptor, LDL receptor, and corticosterone.
9. An injectable drug comprising a monosubstituted 1,2,4,5-tetrazine compound modified with a cross-linking group, wherein the cross-linking group comprises an NHS-active ester, an acyl chloride or a sulfonyl fluoride; the injectable drug is used to anchor a protein drug subsequently injected into the same site, in, The protein drug is modified by trans-cyclooctene.
10. The injectable drug according to claim 9, comprising a compound having a general structural formula as shown in any one of (Formula I) to (Formula VIII): in, Ra is hydrogen, and Rb, Rc, Rd, Re, and Rf are optional: Hydrogen or phenyl, Substituted phenyl, containing hydrogen, halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido, alkanoyl or alkynyl, Substituted alkanoyl containing halogen, alkyl having 1 to 7 carbon atoms, substituted alkyl having 1 to 7 carbon atoms, alkoxy having 1 to 7 carbon atoms, azido or azide, unsubstituted alkanoyl or alkynyl, acyl, Substituted acyl groups contain hydrogen, halogen, alkyl groups having 1 to 7 carbon atoms, substituted alkyl groups having 1 to 7 carbon atoms, alkoxy groups having 1 to 7 carbon atoms, azido groups, alkanoyl groups or alkynyl groups; or a salt, solvate or prodrug of the compound.
11. The method according to claim 1 or the injectable medicine according to claim 9, It is characterized in that The method or the injected drug is used for in situ cross-linking, bioorthogonal reaction, biomolecule labeling, drug delivery, and protein function regulation.
12. Use of a 1,2,4,5-tetrazine compound for anchoring a protein, wherein the protein is a protein modified with trans-cyclooctene.
13. Use of a 1,2,4,5-tetrazine compound for preparing a protein-anchoring drug, wherein the protein-anchoring drug is used for anchoring a protein modified by trans-cyclooctene.
Citation Information
Patent Citations
TCO conjugates and methods for delivery of therapeutic agents
CN106659796A
Tetrazine conjugates for in vivo targeted delivery of payloads
CN118369123A
